Sitafloxacin
From Wikipedia, the free encyclopedia
 |
|
|
Sitafloxacin
|
|
| Systematic (IUPAC) name | |
| 7- [(4S)- 4-amino- 6-azaspiro [2.4] heptan- 6-yl]- 8-chloro- 6-fluoro- 1- [(2S)- 2-fluorocyclopropyl]- 4-oxoquinoline- 3-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H18ClF2N3O3 |
| Mol. mass | 409.81 |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | Oral |
Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.
[edit] See also
[edit] References
- (Japanese) Gracevit グレースビット (PDF) Daiichi Sankyo Co. January 2008.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
